Efrat Kurtzwald-Josefson1, Edith Hochhauser2, Katia Bogachenko3, Shiraz Harun-Khun4, Guy Katz5, Dan Aravot2, Jonathan G Seidman6, Christine E Seidman6, Michael Eldar4, Asher Shainberg3, Michael Arad7. 1. Leviev Heart Center, Sheba Medical Center, Tel Hashomer and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Cardiac Research Lab, Felsenstein Medical Research Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. 2. Cardiac Research Lab, Felsenstein Medical Research Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. 3. Faculty of Life Sciences, Bar Ilan University, Ramat Gan, Israel. 4. Leviev Heart Center, Sheba Medical Center, Tel Hashomer and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. 5. Pinchas Borenstein Talpiot Medical Leadership Program, Department of Obstetrics and Gynecology, Sheba Medical Center, Tel Hashomer and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Leviev Heart Center, Sheba Medical Center, Tel Hashomer and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. 6. Department of Genetics, Harvard Medical School, Boston, Massachusetts. 7. Leviev Heart Center, Sheba Medical Center, Tel Hashomer and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: michael.arad@sheba.health.gov.il.
Abstract
BACKGROUND: Spontaneous calcium release evoking delayed afterdepolarization is believed to cause catecholaminergic polymorphic ventricular tachycardia (CPVT), a lethal human arrhythmia provoked by exercise or emotional stress. β-Adrenergic blockers are the drug of choice, but fail to achieve complete arrhythmia control in some patients. These individuals often require flecainide, device implantation, and/or sympathetic denervation. OBJECTIVE: To optimize the arrhythmia therapy by pharmacological inhibition of the sympathetic nervous system in the homozygous calsequestrin knockout (CASQ2(Δ/Δ)) mouse model of CPVT2. METHODS: A heart telemetry device was implanted for continuous electrocardiographic recording at rest and during provocation testing. Calcium transients and abnormal calcium release were studied in cardiomyocytes isolated from adult mice. Adrenergic receptor expression was determined by using Western blotting and confocal microscopy. RESULTS: Adult CASQ2(Δ/Δ) mice suffer from complex ventricular arrhythmia at rest and ventricular tachycardia during treadmill exercise and after epinephrine injection. β-Adrenergic blockers, propranolol and metoprolol, attenuated arrhythmia at rest but not after stress. Reserpine had no efficacy in controlling arrhythmia. Agents with α-blocking activity, phentolamine or labetalol, abolished both exercise- and epinephrine-induced arrhythmia. In contrast, injection of α-adrenergic agonist phenylephrine reproducibly provoked ventricular tachycardia. Isolated cardiomyocytes from CASQ2(Δ/Δ) mice had delayed calcium release waves upon exposure to sympathetic agonists, which were abolished by phentolamine. Hearts of calsequestrin-mutant mice expressed more α1-adrenergic receptor than did wild type control mice (P < .05). CONCLUSION: We identified a contribution of the α-adrenergic pathway to the pathogenesis of catecholamine-induced arrhythmia. α-Blockade emerges as an effective therapy in the murine model of CPVT2 and should be tried in humans resistant to β-blockers.
BACKGROUND: Spontaneous calcium release evoking delayed afterdepolarization is believed to cause catecholaminergic polymorphic ventricular tachycardia (CPVT), a lethal humanarrhythmia provoked by exercise or emotional stress. β-Adrenergic blockers are the drug of choice, but fail to achieve complete arrhythmia control in some patients. These individuals often require flecainide, device implantation, and/or sympathetic denervation. OBJECTIVE: To optimize the arrhythmia therapy by pharmacological inhibition of the sympathetic nervous system in the homozygous calsequestrin knockout (CASQ2(Δ/Δ)) mouse model of CPVT2. METHODS: A heart telemetry device was implanted for continuous electrocardiographic recording at rest and during provocation testing. Calcium transients and abnormal calcium release were studied in cardiomyocytes isolated from adult mice. Adrenergic receptor expression was determined by using Western blotting and confocal microscopy. RESULTS: Adult CASQ2(Δ/Δ) mice suffer from complex ventricular arrhythmia at rest and ventricular tachycardia during treadmill exercise and after epinephrine injection. β-Adrenergic blockers, propranolol and metoprolol, attenuated arrhythmia at rest but not after stress. Reserpine had no efficacy in controlling arrhythmia. Agents with α-blocking activity, phentolamine or labetalol, abolished both exercise- and epinephrine-induced arrhythmia. In contrast, injection of α-adrenergic agonist phenylephrine reproducibly provoked ventricular tachycardia. Isolated cardiomyocytes from CASQ2(Δ/Δ) mice had delayed calcium release waves upon exposure to sympathetic agonists, which were abolished by phentolamine. Hearts of calsequestrin-mutant mice expressed more α1-adrenergic receptor than did wild type control mice (P < .05). CONCLUSION: We identified a contribution of the α-adrenergic pathway to the pathogenesis of catecholamine-induced arrhythmia. α-Blockade emerges as an effective therapy in the murine model of CPVT2 and should be tried in humans resistant to β-blockers.
Authors: Jérémy Fauconnier; Johanna T Lanner; Shi-Jin Zhang; Pasi Tavi; Joseph D Bruton; Abram Katz; Håkan Westerblad Journal: Diabetes Date: 2005-08 Impact factor: 9.461
Authors: H Lahat; M Eldar; E Levy-Nissenbaum; T Bahan; E Friedman; A Khoury; A Lorber; D L Kastner; B Goldman; E Pras Journal: Circulation Date: 2001-06-12 Impact factor: 29.690
Authors: Alex V Postma; Isabelle Denjoy; Theo M Hoorntje; Jean-Marc Lupoglazoff; Antoine Da Costa; Pascale Sebillon; Marcel M A M Mannens; Arthur A M Wilde; Pascale Guicheney Journal: Circ Res Date: 2002-10-18 Impact factor: 17.367
Authors: Silvia G Priori; Carlo Napolitano; Mirella Memmi; Barbara Colombi; Fabrizio Drago; Maurizio Gasparini; Luciano DeSimone; Fernando Coltorti; Raffaella Bloise; Roberto Keegan; Fernando E S Cruz Filho; Gabriele Vignati; Abraham Benatar; Angelica DeLogu Journal: Circulation Date: 2002-07-02 Impact factor: 29.690
Authors: Karolina Pytka; Klaudia Lustyk; Elżbieta Żmudzka; Magdalena Kotańska; Agata Siwek; Małgorzata Zygmunt; Agnieszka Dziedziczak; Joanna Śniecikowska; Adrian Olczyk; Adam Gałuszka; Jarosław Śmieja; Anna M Waszkielewicz; Henryk Marona; Barbara Filipek; Jacek Sapa; Szczepan Mogilski Journal: Front Pharmacol Date: 2016-08-03 Impact factor: 5.810
Authors: Shiraz Haron-Khun; David Weisbrod; Hanna Bueno; Dor Yadin; Joachim Behar; Asher Peretz; Ofer Binah; Edith Hochhauser; Michael Eldar; Yael Yaniv; Michael Arad; Bernard Attali Journal: EMBO Mol Med Date: 2017-04 Impact factor: 12.137
Authors: Claire Hopton; Anke J Tijsen; Leonid Maizels; Gil Arbel; Amira Gepstein; Nicola Bates; Benjamin Brown; Irit Huber; Susan J Kimber; William G Newman; Luigi Venetucci; Lior Gepstein Journal: Physiol Rep Date: 2022-04
Authors: Prince J Kannankeril; M Benjamin Shoemaker; Kathryn A Gayle; Darlene Fountain; Dan M Roden; Bjorn C Knollmann Journal: Europace Date: 2020-04-01 Impact factor: 5.214